A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 μg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight

European Journal of Contraception and Reproductive Health Care

Volumn 12, Issue 3, 2007, Pages 220-228

  Endrikat, Jan ^a,c   Sandri, Mirella ^a   Gerlinger, Christoph ^b   Rübig, Alexander ^a   Schmidt, Werner ^c   Fortier, Michel ^d  

^a Bayer Inc   (Canada)

^b BAYER PHARMA AG   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d Clinique Recherche en Santé des Femmes   (Canada)

Author keywords

Body weight; Drospirenone; Water retention

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL;

ABDOMINAL PAIN; ADULT; ARTICLE; BODY WEIGHT; CANADA; CLINICAL TRIAL; COLITIS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EDEMA; FEMALE; HERPES ZOSTER; HUMAN; MASTALGIA; MENSTRUATION; MENTAL DISEASE; MENTAL INSTABILITY; MOOS MENSTRUAL DISTRESS QUESTIONNAIRE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; QUESTIONNAIRE; VERTIGO; WATER RETENTION;

ADULT; ALDOSTERONE ANTAGONISTS; ANDROSTENES; BODY WATER; BODY WEIGHT; CANADA; CONTRACEPTIVES, ORAL, COMBINED; EDEMA; ETHINYL ESTRADIOL; FEMALE; HUMANS; PREMENSTRUAL SYNDROME; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 34548301241     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.1080/13625180701440818     Document Type: Article

References (19)

1. Logue C, Moos R. Perimenstrual symptoms: Prevalence and risk factors. Psychosom Med 1986;48:388-414.
2. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000;5:25-34.
3. Parsey KS, Pong A. An open-label, multi-centered study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000;61:105-11.
4. Muhn P, Krattenmacher R, Beier S, et al. Drospirenone: A novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception 1995;51:99-110.
5. Foidart JM, Oelkers W, Heithecker R. Drospirenone: A novel progestogen with antimineralocorticoid and antiandrogenic activity: A major breakthrough in tomorrow's oral contraception. Gynecol Snapshot 1995;3:13-17.
6. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier K-H. The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and antiandrogenic potential. Contraception 1996;54:243-51.
7. Oelkers W, Foidart J-M, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-21.
8. Oelkers W, Helmerhorst FM, Wuttke W, et al. Effect of an oral contraceptive containing drospirenone on the renin-aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000;14:204-13.
9. Moos RH. The development of a menstrual distress questionnaire. Psychosom Med 1968;30:843-67.
10. Moos RH. Menstrual distress questionnaire. Western Psychological Services, 12031 Wilshire Boulevard, Los Angeles, California 90025-1251.
11. Abplanalp JM, Donnelly AF, Rose RM. Psychoendocrinology of the menstrual cycle: I. Enjoyment of daily activities and moods. Psychosom Med 1979;41:587-604.
12. Akker O, Steptoe A. The pattern and prevalence of symptoms during the menstrual cycle. Brit J Psych 1985;147:164-9.
13. Moos RH, Leiderman DB. Toward a menstrual cycle symptom typology. J Psychosom Res 1978;22:31-40.
14. Ross C, Coleman G, Stojanovska C. Prospectively reported symptom change across the menstrual cycle in users and non-users of oral contraceptives. J Psychosom Obstet Gynecol 2003;24:15-29.
15. Borenstein J, Yu HT, Wade S, et al. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med 2003;48:79-85.
16. Barbosa IC, Filho CI, Faggion D, Baracat EC. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 mcg and ethinylestradiol 15 mcg (Minesse). Contraception 2006;73:30-3.
17. Bruni V, Croxatto H, De La Cruz J, et al. A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene- and monophasic desogestrel-containing oral contraceptives. Gynecol Endocrinol 2000;14:90-8.
18. Brown C, Ling F, Wan J. Effect of a new monophasic oral contraceptive on perimenstrual symptoms. Obstet Gynecol 2001;97 Suppl:9S.
19. Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000;5:124-34.